TB-500
The thymosin beta-4 fragment behind recovery research
What TB-500 is, how it is thought to work, how it is typically dosed, what the evidence actually shows, and its legal status in 2026.
BIOSTACKIQThe proposed mechanism
Thymosin beta-4 is found in nearly every human cell. TB-500 is designed to copy its actin-binding activity.
Binds actin
Thymosin beta-4 binds G-actin, a building block of the cell's internal skeleton.
Cells move
That is thought to help repair cells migrate toward an injury.
New blood vessels
It is also studied for angiogenesis, which supports healing tissue.
Well-supported biology for the parent molecule. Whether the fragment does the same in people has not been tested.
TB-500 vs thymosin beta-4
The names get used interchangeably. Scientifically, they are not the same thing.
| Thymosin beta-4 | TB-500 | |
|---|---|---|
| What it is | Natural, full-length peptide (43 amino acids) | Synthetic peptide built around its actin-binding region |
| Human trials | Early-phase trials in chronic wounds and dry eye | None published |
| Animal research | Extensive | Wound, tissue and cardiac repair models |
What is sold as "TB-500" varies by seller: some vials contain the short fragment, others full-length thymosin beta-4. Check the COA.
How TB-500 is typically dosed
No human dose-finding trial exists. These are community conventions, not validated doses.
Twice weekly on non-consecutive days (e.g. Monday and Thursday), subcutaneously, usually the abdomen.
Some step down to weekly after loading. Many injury protocols simply stop after 4 to 6 weeks.
No post-cycle therapy is used; TB-500 doesn't act on testosterone. Mixing math: TB-500 dosage calculator. Paired with BPC-157: stack guide.
What the research shows
Real science behind the parent molecule; very little behind the product.
Thymosin beta-4 helps cells migrate and supports new blood vessels across many tissue-injury models.
Goldstein et al., Trends Mol Med 2005 (PMID 16153892)
Early-phase trials in chronic wounds and dry eye tested the full molecule, not the fragment sold as TB-500.
Everything about its effects in people is extrapolated from animal work and the parent molecule.
Same applies to the BPC-157 pairing
Safety and unknowns
- Injection-site reactions: redness, swelling or bruising are the most commonly reported effects.
- Cancer history: thymosin beta-4 is studied in cancer research because higher levels are linked to tumor growth and spread in lab and animal work. Not shown in people, but a real reason to avoid it with a current or past cancer.
- Long-term effects: unknown. No long-term human safety data exists.
- Quality: research chemical vials vary in identity and purity.
More in peptide side effects.

TB-500's legal status in 2026
Prescription compounding
Under the October 2026 draft HHS policy, licensed 503A pharmacies can compound TB-500 by prescription, by injection only, single-ingredient and fully tested.
Not FDA-approved
FDA's advisory panel voted to recommend it in July 2026, but it is not on the 503A list yet. Research chemical versions are not covered.
Banned in sport
Thymosin beta-4 and its fragments are on the WADA prohibited list at all times.
Updates: FDA peptide status tracker · the 2026 peptide update.
Know if it's working
Injuries improve on their own over time. A simple log is how you tell whether TB-500 added anything.
- Each injection, with date and site
- Pain and range of motion, scored weekly
- Loading and maintenance phases on one timeline
The Protocol Builder handles twice-weekly schedules, alongside daily BPC-157 if you stack them.

Frequently asked questions
What is TB-500?
TB-500 is a synthetic peptide based on thymosin beta-4, a naturally occurring peptide found in nearly all human cells that helps regulate actin, cell migration and tissue repair. It is studied in animal models for wound healing and recovery in muscle, heart and connective tissue.
What is the difference between TB-500 and thymosin beta-4?
Thymosin beta-4 is the natural, full-length 43-amino-acid peptide. TB-500 is a synthetic peptide built around its actin-binding region. The early-phase human trials that exist were run on full-length thymosin beta-4, not on TB-500. What is sold as TB-500 also varies by seller, so checking the certificate of analysis matters.
What is the typical TB-500 dose?
No human dose-finding trial exists. Community protocols commonly use a loading phase of 2 to 2.5mg per injection twice weekly for about 4 to 6 weeks, sometimes followed by a maintenance phase of about 2mg once weekly. These are informal conventions, not validated clinical doses.
Has TB-500 been tested in humans?
TB-500 itself has not been the subject of published human clinical trials. Early-phase human trials exist for full-length thymosin beta-4 in chronic wound healing and dry eye, but that is a different molecule from the fragment commonly sold as TB-500.
Is TB-500 legal in 2026?
TB-500 is not FDA-approved. Under a draft HHS enforcement discretion policy published October 30, 2026, licensed 503A compounding pharmacies can compound TB-500 for individual patients with a valid prescription, by injection only, under strict sourcing, testing and labeling conditions. Research chemical versions sold online are not covered.
Does TB-500 cause cancer?
No study has shown TB-500 causes cancer in people. Thymosin beta-4 is studied in cancer research because higher levels are associated with tumor growth and spread in lab and animal studies, so anyone with a current or past cancer should avoid it and talk to their oncologist.
Can athletes use TB-500?
Not if they are drug tested. Thymosin beta-4 and its fragments, including TB-500, are prohibited at all times under the World Anti-Doping Agency list.
Does TB-500 need to be cycled?
Most protocols run a 4 to 6 week loading phase, sometimes followed by a few weeks of once-weekly maintenance, then a break before repeating. Neither the cycle length nor the break comes from controlled human trial data.
Where to buy: the prescription route, COA checks and today's price, in where to buy TB-500.
Plan your TB-500 protocol
Set loading and maintenance phases, add BPC-157 if you stack them, and log every injection. Free.
Sources
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. PMID 16153892
- Thymosin β4: a potential molecular target for tumor therapy. PMID 22856429
- U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register, October 30, 2026. federalregister.gov
- World Anti-Doping Agency. The Prohibited List. wada-ama.org
This content is for informational purposes only and is not medical advice. TB-500 is not FDA-approved, and its human evidence is limited to a related but distinct parent molecule. Always consult a qualified healthcare provider before starting any peptide protocol.